Mubritinib
- CAS No.
- 366017-09-6
- Chemical Name:
- Mubritinib
- Synonyms
- CS-522;TAK 165;MUBRITINIB;TAK165;TAK-165;Mubritinib(TAK 165);Mubritinib USP/EP/BP;(E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;(E)-4-((4-(4-(1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-
- CBNumber:
- CB21011746
- Molecular Formula:
- C25H23F3N4O2
- Molecular Weight:
- 468.47
- MOL File:
- 366017-09-6.mol
- Modify Date:
- 2023/6/30 15:45:59
| Melting point | 158.0 to 162.0 °C |
|---|---|
| Boiling point | 620.9±65.0 °C(Predicted) |
| Density | 1.25±0.1 g/cm3(Predicted) |
| storage temp. | Store at +4°C |
| solubility | DMSO : 50 mg/mL (106.73 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| pka | 1.45±0.10(Predicted) |
| form | powder to crystal |
| color | White to Gray to Brown |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H320-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
| HS Code | 2934.99.4400 |
Mubritinib price More Price(4)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML1312 | Mubritinib ≥98% (HPLC) | 366017-09-6 | 5MG | ₹6711.5 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML1312 | Mubritinib ≥98% (HPLC) | 366017-09-6 | 25MG | ₹27214.05 | 2022-06-14 | Buy |
| TCI Chemicals (India) | M3058 | Mubritinib | 366017-09-6 | 25MG | ₹8800 | 2022-05-26 | Buy |
| TCI Chemicals (India) | M3058 | Mubritinib | 366017-09-6 | 100MG | ₹28500 | 2022-05-26 | Buy |
Mubritinib Chemical Properties,Uses,Production
Uses
Mubritinib is used in selective targeting of CTNNB1-, KRAS-or MYC-driven human cancer cell growth by combinations of existing drugs
Biological Activity
Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo .
Mubritinib Preparation Products And Raw materials
Raw materials
Preparation Products
Global( 150)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | China | 32760 | 60 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29898 | 58 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | China | 39916 | 58 | Inquiry |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | China | 49391 | 58 | Inquiry |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | China | 24639 | 58 | Inquiry |
| Baoji Guokang Bio-Technology Co., Ltd. | 0917-3909592 13892490616 | China | 9322 | 58 | Inquiry |
| Sinoway Industrial co., ltd. | 0592-5800732; +8613806035118 | China | 990 | 58 | Inquiry |
366017-09-6(Mubritinib)Related Search:
chevron_left
1of4
chevron_right
MUBRITINIB
1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
TAK 165
Mubritinib(TAK 165)
(E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole Mubritinib (TAK 165)
Mubritinib 1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole
(E)-4-((4-(4-(1H-1,2,3-Triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
CS-522
TAK165;TAK-165
1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-
Mubritinib USP/EP/BP
366017-09-6
C25H23F3N4O2
Inhibitors